Health Stocks Sway as Weight-Loss Drugs Hit and Miss
Published on: Aug. 20, 2025, 2:28 a.m. | Source: Devdiscourse
Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate health forecasts decline slightly, while the weight-loss drug market sees continued growth amid new treatments and strategic shifts in biotech firms.
